DAVID C. NOLAN, M.D.; CARL B. LAUTER, M.D.; A. MARTIN LERNER, M.D., F.A.C.P.
NOLAN DC, LAUTER CB, LERNER AM. Idoxuridine in Herpes Simplex Virus (Type 1) Encephalitis: Experience with 29 Cases in Michigan, 1966 to 1971. Ann Intern Med. 1973;78:243-246. doi: 10.7326/0003-4819-78-2-243
Download citation file:
Published: Ann Intern Med. 1973;78(2):243-246.
We studied 29 patients with herpes simplex virus, type 1, encephalitis in Michigan between 1966 and 1971. Twenty patients were treated intravenously with idoxuridine at doses of up to 86 mg/kg body weight per day for 5 days. Overall mortality (among patients surviving for 48 hours after hospitalization) in the treated and supportive groups was 33%. Mortality was greatest in patients over 50 years of age (67%). However, 9 of the 12 idoxuridine-treated survivors are well today, whereas 1 of the 6 nontreated living patients is well. If 54 mg/kg body weight of idoxuridine is given intravenously for 5 days in two divided, rapid infusions (50 mg/min), pharmacologic effects are maximal and toxicity minimal. No patient should be given a total dose of more than 20 g of idoxuridine.
Learn more about subscription options.
Register Now for a free account.
CNS Infections, Infectious Disease, Neurology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only